Ironwood Pharmaceuticals and Forest Laboratories announced they will be reporting additional clinical data from their Phase 2b studies for linaclotide, an investigational compound for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC). Linaclotide demonstrated proof of concept in the Phase 2b program, comprised of two clinical studies in over 700 patients with either IBS-C or CC. In patients with IBS-C, linaclotide significantly reduced abdominal pain and bloating and improved bowel function throughout the 12-week treatment period. In patients with CC, linaclotide reduced constipation throughout the 4-week treatment period.

Linaclotide is an orally available agonist of guanylate cyclase type-C, a receptor found on the lining of the intestine.

For more information call (800) 678-1605 or visit www.frx.com.